Log in to search using one of your social media accounts:

 

Treatment of Peripheral T-Cell Lymphoma in Community Settings
Conclusions The significant variability in treatments used for PTCL emphasizes the lack of consensus therapy in this rarer lymphoma and calls for additional organized prospective and registry studies to evaluate comparative effectiveness. Teaser Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of malignancies which do not have consensus treatment recommendations. This retrospective review of 93 patients treated in community settings demonstrated considerable variability in treatment strategies. First-line CHOP and CHOP-like regimens were used in 74% of patients, providing 4-year overall survival...
Source: Clinical Lymphoma Myeloma and Leukemia - May 10, 2017 Category: Cancer & Oncology Source Type: research

Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of first-line therapy, but long overall survival: results of a population-based cohort in British Columbia, Canada
Conclusions Although median TFS of 11q- patients in this cohort is short at 2.5 years, OS remains long at 14.7 years, even when the majority of patients received initial treatment without alkylators. Teaser This study documents the clinical course of 67 with high-risk CLL patients with 11q- deletion, from a Provincial CLL database. Aklylator-containing chemotherapies are thought to required to overcome the adverse prognosis associated with 11q-. However, most 11q- patients did not receive alkylators first line and had a median survival of 14.7 years, comparable to the rest of the cohort. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 9, 2017 Category: Cancer & Oncology Source Type: research

Increased Mutational Burden and Alterations to DNA Damage Repair Genes are Associated With Poor Prognosis and Sensitivity to PI3K-mTOR Inhibitors in Multiple Myeloma
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement Author(s): Muntasir Mamun Majumder, David Tamborero, Pekka Anttila, Raija Silvennoinen, Juha Lievonen, Samuli Eldfors, Ashwini Kumar, Alun Parsons, Minna Suvela, Esa Jantunen, Kimmo Porkka, Caroline Heckman (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Integrating Molecular Genetic and Gene Expression Profiling Allows Stratification of Ultra-High Risk Myeloma
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement Author(s): Amy Sherborne, Dil Begum, Amy Price, David Johnson, Sidra Ellis, Charlotte Smith, Fabio Mirabella, Karen Menezes, Vallari Shah, Scott Kimber, John Jones, Charlotte Pawlyn, Richard Houlston, Nigel Russell, Matthew Jenner, Gordon Cook, Alina Striha, Corinne Collett, Anna Waterhouse, Walter Gregory, David Cairns, Mark Drayson, Roger Owen, Faith Davies, Gareth Morgan, Graham Jackson, Martin Kaiser (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Non-overlapping Promoter and Super-enhancer Driven Processes Support Myeloma Cell Growth and Survival via Distinct Regulatory Axes
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement Author(s): Mariateresa Fulciniti, Charles Lin, Mehmet Samur, Rick Young, Kenneth C. Anderson, Herve Avet-Loiseau, James Bradner, Nikhil Munshi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Workshop
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17  Abnormalities in B-Cell Acute Lymphoblastic Leukemia
Conclusion In contrast to the patients with acute myeloid leukemia, our results show that MK and CK do not play a predictive role in patients with B-ALL, but further study is required to determine whether specific changes on chromosome 17 might have prognostic value when investigated separately. Micro-Abstract The effect of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Our results showe...
Source: Clinical Lymphoma Myeloma and Leukemia - April 11, 2017 Category: Cancer & Oncology Source Type: research

Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
Conclusion Incidence and survival of ALK-positive ALCL varies significantly with patients' demographic characteristics as identified in our study. Treatment strategies need to be tailored accordingly to address these variations and ensure uniform access to care. Micro-Abstract We used the Surveillance, Epidemiology, and End Results database to study the incidence and survival of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. We found that the disease incidence varied significantly by age, gender, and race, whereas survival was influenced by age, race, stage, period of diagnosis, and radiotherapy. ...
Source: Clinical Lymphoma Myeloma and Leukemia - April 11, 2017 Category: Cancer & Oncology Source Type: research

Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??
Conclusion Use of BM parameters, a simple mean that is feasible in routine clinical practice could improve prognostic efficacy of Sokal score with regards to PFS, but not the OS in low and intermediate risk groups. Further research to improve sensitivity of risk scores to prognosticate CML-CP and attempts at risk directed therapy is warranted. Teaser Development of various risk scores for chronic myeloid leukemia prognostication and intensification of treatment accordingly has been an area of research. Our data confirms that by using bone marrow parameters instead of conventional peripheral blood parameters we could improv...
Source: Clinical Lymphoma Myeloma and Leukemia - March 31, 2017 Category: Cancer & Oncology Source Type: research

The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia
Conclusion Although it might be feasible to use pediatric-inspired protocols in this age group, toxicity cannot be overlooked, and the application of these protocols might require modification of drug doses or schedules relative to those used for younger children. Moreover, additional surveillance and supportive measures should be implemented to maximize benefits while minimizing toxicity. Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survi...
Source: Clinical Lymphoma Myeloma and Leukemia - March 24, 2017 Category: Cancer & Oncology Source Type: research

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Conclusion These data have demonstrated that, in contrast to the historically poor results with standard influenza vaccination, this novel high-dose booster vaccination strategy leads to high rates of seroprotection. Randomized controlled studies are needed to compare this novel strategy to the standard vaccination strategy. Micro-Abstract The goal of the present study was to evaluate a novel prospective influenza vaccination strategy for patients with plasma cell disorders. Fifty-one patients were treated with a 2-dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerate...
Source: Clinical Lymphoma Myeloma and Leukemia - March 24, 2017 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): L. Max Almond, Maria Charalampakis, Samuel J. Ford, David Gourevitch, Anant Desai Myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare condition, most often associated with acute myeloid leukemia (AML), although in some rare cases it may present in nonleukemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site, leading to very varied clinical presentations. Diagnosis is challenging and relies on a high ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 23, 2017 Category: Cancer & Oncology Source Type: research

Elderly Patients with Chronic Myeloid Leukemia Benefit from a Dasatinib dose as Low as 20 mg
Conclusion Low-dose (e.g., ≤ 20 mg) dasatinib therapy generates an adequate molecular response in most elderly CML-CP patients without causing severe AEs. Teaser A retrospective study of elderly chronic myeloid leukemia (CML) patients aged ≥ 65 years was conducted to evaluate the efficacy and safety of low-dose dasatinib treatment. Reducing the dose of dasatinib below 100 mg/day (even to ≤ 20 mg/day) generated good responses in these patients. The doses were safe and induced rapid and deep molecular responses. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 18, 2017 Category: Cancer & Oncology Source Type: research

Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2016
Publication date: Available online 18 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Evangelos Terpos (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 18, 2017 Category: Cancer & Oncology Source Type: research

Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China
Conclusions General clinical features were comparable with those of Western patients, whereas therapeutic outcomes were slightly inferior. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying 3 subsets of patients with significantly distinct outcomes, which warrants further validations. Micro-Abstract One hundred and fifty patients with newly diagnosed Hodgkin's lymphoma at 4 medical centers over a decade were reviewed. General clinical features were comparable to western patients, while therapeutic outcomes were slightly inferior. A new risk model incorporating traditional ris...
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2017 Category: Cancer & Oncology Source Type: research

Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients
Conclusion Although ZA did not improve OS in patients with MM; it continued to be useful to reduce skeletal events, and thus improve better quality of life for patients. Micro-Abstract To assess whether prolonged use of zoledronic acid (ZA; 4 years) improves outcome in multiple myeloma patients, we performed a clinical trial to compare the effect of 48 and 24 months of treatment. A total of 170 patients were randomly assigned to the 2 groups in the trial. Overall survival was not improved, however, the ZA group showed a reduced number of skeletal events. Thus, we suggest that ZA should be considered to be used for longer d...
Source: Clinical Lymphoma Myeloma and Leukemia - March 8, 2017 Category: Cancer & Oncology Source Type: research

Thoracic Complications in Chronic Lymphocytic  Leukemia
Conclusion Thoracic manifestations in CLL are common among hospitalized patients. Although infectious pneumonia remains most common, unusual or opportunistic infections may be increasing, and direct lung damage owing to CLL itself or to newer biologic agents are being diagnosed with lung tissue sampling. Recognition of these complications will allow earlier diagnosis, which may change management including removal of offending biologic agents or augmentation of treatment for CLL when infiltrative leukemic cells are present. Micro-Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. Patients with CL...
Source: Clinical Lymphoma Myeloma and Leukemia - March 8, 2017 Category: Cancer & Oncology Source Type: research

The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia
Conclusion Our results lead us to conclude that generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. However, first-line generic imatinib showed suboptimal efficacy compared with branded imatinib. Micro-Abstract We examined the long-term clinical outcomes of patients with chronic myeloid leukemia (n = 41) receiving generic imatinib as first-line (n = 27) and second-line therapy (n = 14) in Bosnia and Herzegovina. Overall survival rates for first-line and second-line generic imatinib were 85% and 100%, respectively. For first-line generic imatinib, complete cytogeneti...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Treating Multiple Myeloma Patients with Oral Therapies
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Shaji Kumar, Ravi Vij, Stephen J. Noga, Deborah Berg, Lonnie Brent, Lawrence Dollar, Ajai Chari Recent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment burden continues to negatively impact the real-world duration of MM therapy, and strategies to limit the adverse impact of treatment on patient quality of life are therefore particularly important. Oral MM therapies include the immunomodulatory drugs lenalidomide, thalidomide and...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma: Presentation, Diagnosis and Treatment
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): L. Max Almond, Maria Charalampakis, Samuel Ford, David Gourevitch, Anant Desai Myeloid sarcoma is an extramedullary tumour of immature granulytic cells. It is a rare condition, most often associated with acute myeloid leukaemia although in some rare cases it may present in non-leukaemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site leading to very varied clinical presentations. Diagnosis is challenging and relies on a high index of ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Efficacy and safety of bendamustine and ibrutinib in previously untreated patients with Chronic Lymphocytic Leukemia – indirect comparison
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Iga Andrasiak, Justyna Rybka, Wanda Knopinska-Posluszny, Tomasz Wrobel (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Waldenstr öm Macroglobulinemia: Review of Pathogenesis and Management
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Seongseok Yun, Ariel Johnson, Onyemaechi Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz, Faiz Anwer Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M (IgM). Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of n...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial
Conclusions These data demonstrate that in contrast to historically poor results with standard influenza vaccination, this novel high-dose booster vaccination strategy leads to high rates of seroprotection. Randomized controlled studies are needed to compare this to standard vaccination strategy. Teaser The goal of the present study was to evaluate a novel prospective influenza vaccination strategy in patients with plasma cell disorders. Fifty-one patients were treated with a two dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated led to very high rates of seroprot...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Thoracic Complications in Chronic Lymphocytic Leukemia (Thoracic Diseases in CLL)
Publication date: Available online 17 February 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Background Chronic Lymphocytic Leukemia (CLL) is the most common lymphoproliferative disorder worldwide. While thoracic complications are frequent in CLL, only limited data exist regarding the etiologies of these complications. Methods A retrospective chart review was performed on all patients admitted to a tertiary care, CLL-referral center, with CLL and a respiratory complaint from 2001 through 2013 to categorize pulmonary complaints and diagnoses. Fi...
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Clinical features and prognosis analysis of Hodgkin ’s lymphoma: A multicenter retrospective study over a decade of patients in China
Conclusions General clinical features were comparable to western patients, whereas therapeutic outcomes were slightly inferior. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying 3 subsets of patients with significantly distinct outcomes, which warrants further validations. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 abnormalities in B-Cell Acute Lymphoid Leukemia
Publication date: Available online 17 February 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Priya Khoral, Eshetu G. Atenafu, Kenneth J. Craddock, Aaron Schimmer, Hong Chang The impact of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities (abnl 17) on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Older age (>60), higher white blood cell count (>30), and abnl 17 were associated with shorter overall survival on...
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Prolonged Use of Zoledronic ACID ( 4 years) Did Not Improve Outcome In Multiple Myeloma Patients
Conclusions Although ZA did not improve OS in patients with MM; continue to be useful to reduce skeletal events, thus improving better quality of life to the setting of patients. Teaser To assess were prolonged use of zoledronic acid (ZA:4 years) improves outcome in multiple myeloma (MM)patients, we performed a clinical trial, for compared the effect of 48 and 24 months.A total of 170 patients were randomly assigned, to the two groups in the trial.The overall survival was not improved. However ,ZA retain to reduce the number of skeletal events. Thus, we suggested that ZA , will be considered to be employed for longer durat...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Whole Body MR imaging: A Useful Imaging Modality in the Management of Children with Acute Myeloid Leukemia
Conclusion Chloromas tended to show multiplicity and be presented without symptoms. The most common site of involvement was musculoskeletal system. Whole body MR imaging provided additional information that affected clinical management in children with AML. Teaser Children with acute myeloid leukemia suffer from various complications such as chloromas and disseminated infection or inflammation during their illness. As these complications tend to involve everywhere in the body, whole body MR imaging may be a useful tool in children with acute myeloid leukemia. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Systemic Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
Conclusion Incidence and survival of ALK positive ALCL varies significantly with patients’ demographic characteristics as identified in our study. Treatment strategies need to be tailored accordingly to address these variations and ensure uniform access to care. Teaser We used the SEER database to study the incidence and survival of ALK positive ALCL. We found that the disease incidence varied significantly by age, gender and race, while survival was influenced by age, race, stage, period of diagnosis and radiotherapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

The Dana Farber Consortium Protocol (DFCP) for the treatment of adolescents and young adults with acute lymphoblastic leukemia: a single institution experience in Saudi Arabia
Conclusion Although it might be feasible to use pediatric-inspired protocols in this age group, toxicity cannot be overlooked, and the application of these protocols might require modification of drug doses or schedules relative to those used for younger children. Moreover, additional surveillance and supportive measures should be implemented to maximize benefits while minimizing toxicity. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies
We present a single-center, large cohort, retrospective study of the efficacy of involved field radiation therapy (IFRT) in ocular adnexal lymphoproliferative disorders (OALDs). Failure free survival (FFS), complete remission (CR), and local, regional and distant failure were determined for 112 patients with marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) OALDs (n=71) and non-MALT OALDs (n=41) cohorts. Fifty-six patients with MALT OALD and 26 patients with non-MALT OALD received IFRT only (without any planned concurrent or sequential systemic chemo- or chemo-immunotherapies). Among these OALD cohorts tre...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
Conclusion Our results lead us to conclude that generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. However, first-line generic imatinib showed suboptimal efficacy compared to branded imatinib. Teaser We examined the long-term clinical outcomes of CML patients (n=41) receiving generic imatinib as first-line (n=27) and second-line therapy (n=14) in Bosnia and Herzegovina. OS rates for first-line and second-line generic imatinib were 85% vs. 100%, respectively. For first-line generic imatinib, CCyR was 81%. Generic imatinib as second-line therapy does not have deleterious effects on...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States
Conclusion The diagnostic workup for PTCL in the United States varies widely and often lacks important phenotypic information to fully characterize the lymphoma. Gaps in testing of selected markers should be filled, given the impending revision to the World Health Organization classification. The accuracy of diagnosis will become increasingly important as we enter the era of targeted treatment for PTCL. Micro-Abstract With increased understanding of the unique entities of peripheral T-cell lymphoma (PTCL), subtype-specific approaches are emerging, and more precise diagnoses are becoming increasingly important. Using d...
Source: Clinical Lymphoma Myeloma and Leukemia - February 13, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy
Publication date: Available online 11 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sid Selim, Jerome Rey, Aude Charbonnier, Evelyne D'Incan, Bilal Mohty, Didier Blaise, Norbert Vey (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 9, 2017 Category: Cancer & Oncology Source Type: research

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
Conclusion To the best of our knowledge, the present study is the first description of PRES associated with DA-EPOCH. The key risk factors for the development of PRES identified in our study included hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, a high tumor burden, and the presence of pre-existing CNS insults during chemotherapy, such as CNS infection. Patients with these risk factors appear to have a greater risk of developing PRES and should be monitored closely during treatment. Micro-Abstract The purpose of our study was to identify risk factors for the development of posterior ...
Source: Clinical Lymphoma Myeloma and Leukemia - February 4, 2017 Category: Cancer & Oncology Source Type: research

Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients
Conclusion WT1 expression status represents a good molecular marker of prognosis, response to treatment, and MRD monitoring. Above all, the usage of the WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients could lead to more adapted, personalized treatment protocols. Micro-Abstract The aim of the present study was to test the possibility for the usage of the WT1 (Wilms tumor 1) expression level as an additional biomarker for prognosis and minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia with normal karyotype (AML-NK). We found that overexpress...
Source: Clinical Lymphoma Myeloma and Leukemia - February 2, 2017 Category: Cancer & Oncology Source Type: research

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age
Conclusion Age should not be a limiting factor in considering the modality of AHCT. However, younger patients might also benefit from additional novel treatment approaches in the setting of clinical trials, given their similar outcomes with the older patients in our study. Micro-Abstract Autologous hematopoietic cell transplantation has been shown to prolong survival in patients with multiple myeloma; however, adequate data are lacking for patients aged > 70 years and < 50 years. We retrospectively analyzed and compared the outcomes of patients between the 2 age groups (> 70 vs. ≤ 50 years...
Source: Clinical Lymphoma Myeloma and Leukemia - January 30, 2017 Category: Cancer & Oncology Source Type: research

Myeloma in the Real World: What Is Really Happening?
Publication date: Available online 26 December 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequen...
Source: Clinical Lymphoma Myeloma and Leukemia - January 29, 2017 Category: Cancer & Oncology Source Type: research

The Society of Hematologic Oncology (SOHO): Continuing to Move Forward in the Battle against Hematologic Malignancies
Publication date: Available online 18 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 18, 2017 Category: Cancer & Oncology Source Type: research

Comparative study of L-asparaginase-based LOP regimen over CHOP regimen before radiotherapy for stage IIE extranodal nasal type NK/T cell lymphoma : a study of two centers
Conclusion The results showed that the LOP regimen is safe and much more efficient than CHOP regimen for stage IIE ENKTL patients. It indicates that LOP regimen is a satisfying alternative protocol among the other L-asparaginase-based regimens reported so far, such as SMILE, GELOX, CHOP-L and Sandwich. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second line therapy: a multicener prospective observational study
Conclusion The QOL among patients on nilotinib administered as a second-line therapy was very good and adherence to the treatment was high. The efficacy and safety of the drug were confirmed in the real-life setting. Teaser To evaluate quality-of-life (QOL) and adherence to Nilotinib used as a second line therapy in 177 chronic myeloid leukemia patients in chronic phase a multicenter, prospective observational study was conducted. The QOL was very good and adherence to the treatment was high. Study results could be taken into consideration in the process of TKI treatment choice (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH chemotherapy
Conclusion To our knowledge, this is the first description of PRES associated with DA-EPOCH. Key risk factors for development of PRES identified in our study include hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, high tumor burden and presence of preexisting CNS insults during chemotherapy treatment such as CNS infection. Patients with these risk factors appear to be at higher risk of developing PRES and should be monitored closely during treatment. Teaser The purpose of our study was to identify risk factors for development of posterior reversible encephalopathy syndrome (PRES) follo...
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

More about the risk of Ibrutinib-associated bleeding
Publication date: Available online 10 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ambra Paolini, Valeria Coluccio, Mario Luppi, Marco Marietta (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Peripheral T-Cell Lymphoma Diagnostic Work-Up in the United States
Conclusion The diagnostic work-up for PTCL in the US is widely variable, often lacking important phenotypic information to fully characterize the lymphoma. Gaps in testing of selected markers will need to be filled given the impending revision to the WHO classification. Accuracy of diagnosis will become increasingly important as we enter the era of targeted treatment for PTCL. Teaser With increased understanding of unique entities of peripheral T-cell lymphomas (PTCL), subtype specific approaches are emerging and more precise diagnoses is becoming increasingly important. Using data from a large prospective cohort study, we...
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Evidence for Selective Benefit of Sequential Treatment with Hypomethylating agents in Patients with Myelodysplastic Syndrome (MDS)
Conclusions Enrollment in clinical trial should be the strongly encouraged in HMA failure. Sequential use of HMA could be considered as an alternative approach in the treatment of MDS after first line HMA failure if clinical trials are not available. The outcome of patients with progressive disease after treatment with HMA remains poor and continues to be an unmet need. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Treatment of post transplant relapse of FLT3-ITD mutated AML using 5-azacytidine and sorafenib bitherapy
Publication date: Available online 11 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Selim Sid, Rey Jerome, Charbonnier Aude, D’Incan Evelyne, Mohty Bilal, Blaise Didier, Norbert Vey (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Usage of Wilms ’ Tumor 1 (WT1) Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia with Normal Karyotype (AML-NK) Patients
Conclusion WT1 expression status represents a good molecular marker of prognosis, response to treatment evaluation and MRD monitoring. Above all, the usage of WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients, can lead to more adapted, personalized treatment protocols. Teaser The aim of this study was to test the possibility for the usage of WT1 expression level as an additional biomarker for prognosis and minimal-residual-disease (MRD) monitoring in AML-NK patients. We found that overexpression of WT1 had negative impact on treatment outcome. It was a suitable marker for ...
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Myeloma in the Real World: What ’s really happening?
Publication date: Available online 26 December 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Multiple myeloma (MM) is the second most common haematological malignancy and predominantly a disease of the elderly. In the last two decades a range of new therapeutic options have become available leading to improvements in patient outcomes including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach towards more active management including use of sequential ...
Source: Clinical Lymphoma Myeloma and Leukemia - December 26, 2016 Category: Cancer & Oncology Source Type: research

Prognostic Implications of Monosomies in Patients with Multiple Myeloma
Conclusion In addition to known cytogenetic abnormalities, such as monosomy 13, hypodiploidy and TP53 (17p) deletion, monosomy 16, and loss of the Y chromosome have adverse prognostic implications in patients with MM. Teaser This study evaluated the prevalence and prognostic implications of monosomies in 170 Korean patients with multiple myeloma (MM). Monosomies in chromosomes 16, chromosomes 13, TP53 (17p) deletion, and hypodiploidy had adverse prognostic implications in patients with MM. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 25, 2016 Category: Cancer & Oncology Source Type: research

Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients
Conclusion Results support existing registry data demonstrating that survival for HL has improved over the 4 decades analyzed. This data set is robust and validated, and it adds valuable understanding to the reasons behind the survival curves, which are a balance between efficacious therapies and decreased death related to cardiac conditions and second malignancies. Micro-Abstract Survival for Hodgkin lymphoma has improved over the last 4 decades thanks to reducing the risks of death from primary disease and, expectantly, treatment-related toxicity. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 24, 2016 Category: Cancer & Oncology Source Type: research